Fluocinolone Acetonide Oil Dosing
For scalp psoriasis in adults, apply a thin film of fluocinolone acetonide 0.01% topical oil to wet or dampened hair and scalp, massage well, cover with a shower cap, and leave on overnight or for a minimum of 4 hours before washing off with regular shampoo. 1
Scalp Psoriasis (Adults)
- Application frequency: Once daily (overnight or minimum 4 hours) 1
- Preparation: Wet or dampen hair and scalp thoroughly before application 1
- Technique: Apply thin film to scalp, massage well, cover with shower cap 1
- Removal: Wash hair with regular shampoo and rinse thoroughly 1
Atopic Dermatitis (Children and Infants)
For atopic dermatitis in children aged 3 months and older, apply fluocinolone acetonide 0.01% oil twice daily to affected areas. 2, 3
- Dosing frequency: Twice daily application 2, 3
- Age range: Safe and effective in children as young as 3 months of age 3
- Treatment duration: Typically 2-4 weeks, with 81-87% of patients showing ≥50% improvement within 2 weeks 2
- Body surface area: Can be safely applied to extensive areas (mean 48% body surface area in infants without adrenal suppression) 3
Safety Profile in Children
- No adrenal suppression occurred after 4 weeks of twice-daily treatment in children aged 2-12 years 2 or in infants as young as 3 months 3
- Peanut allergy: Safe to use even in peanut-sensitive patients, as the refined peanut oil contains <0.5 parts per million amino acids 1, 2
- Local adverse effects: Minimal risk of skin atrophy or telangiectasia with appropriate use 1, 2
Otic Eczema
For otic eczema, apply fluocinolone acetonide 0.025% otic solution twice daily for 7 days. 4
- Dosing: Twice daily for 7 days 4
- Efficacy: Significant reduction in itching and otoscopic signs (erythema, edema, scaling) compared to placebo 4
Important Precautions
- Avoid occlusive dressings on areas other than the scalp, as this increases systemic absorption and risk of HPA axis suppression 1
- Facial application: Use with caution; a post-marketing study in children applying to the face twice daily for 4 weeks showed 25.9% experienced adverse events, primarily mild telangiectasia (8.6%) and erythema (5.2%) 1
- Duration limits: For non-scalp applications, limit treatment duration to minimize risk of systemic effects, particularly in children with larger skin surface-to-body mass ratios 1
- Monitoring: Watch for signs of adrenal suppression in children (linear growth retardation, delayed weight gain, low plasma cortisol) if used extensively or for prolonged periods 1